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Late Cerebral Events After
Carotid Artery StentingWe read with great interest the recent paper by Gen-
sicke et al. (1), which reported a 3-fold increased risk of
recurrence of stroke or transient ischemic attack at 6
months in symptomatic patients treated with carotid
artery stenting (CAS) and who showed new silent
ischemic cerebral lesions on diffusion-weighted mag-
netic resonance imaging after the endovascular pro-
cedure. This observation did not apply to patients
treated with carotid endoatherectomy (CEA). The
investigators discussed the possible role of vulnerable
plaques and the potential beneﬁts of longer and more
aggressive antiplatelet therapy. The study provided
highly valuable new scientiﬁc evidence that might
improve the current clinical outcomes of CAS and ge-
nerated a hypothesis that deserves intensive in-
vestigation. However, the previously published ICSS
(International Carotid Stenting Study) data provided
little information on the kind of stent that was used
(2). With cerebral protection, plaque coverage is acritical issue for CAS success; although CEA could
remove almost the entire plaque, carotid stents have a
free area between the struts where plaque prolapse
could happen, with a risk of late embolization (3). It is
well known that the free area surface varies according
to stent design, with signiﬁcant differences between
open- and closed-cell stents; the latter has better pla-
que coverage and a lower incidence of plaque prolapse
(4). Since the ICSS study was performed, new mesh-
covered stents with a small, free-cell area have
become available, which potentially could reduce late
embolization from the stent-covered plaque. A more
aggressive medical therapy in this subset of patients is
advisable, but carotid stent characteristics should be
taken into account when considering the global risk of
late events.*Andrea Pacchioni, MD
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Cerebral Events After Carotid Artery StentingDrs. Pacchioni, Ribichini, and Reimers raise an
important issue about the effects of stent design on
outcomes after carotid artery stenting. The stent
design used was reported for 119 of 124 patients
who underwent stenting for symptomatic carotid
stenosis in the ICSS-MRI (International Carotid
Stenting Study-Magnetic Resonance Imaging) sub-
study; 74 patients (62%) received an open-cell stent
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491(a stent in which not all of the struts were inter-
connected, and the open areas between the struts
were >5 mm2), and 45 patients (38%) received a
closed-cell stent (interconnected struts and open
areas of #5 mm2). The proportion of patients who
showed new ischemic brain lesions on diffusion-
weighted magnetic resonance imaging (DWI) after
treatment did not differ between the former and the
latter groups (n ¼ 37 [50%] vs. n ¼ 22 [49%]), and
neither did the total number of new DWI lesions
when analyzed with a negative binomial regression
model (1).
However, in the long-term follow-up analysis of
the ICSS-MRI substudy (2), we observed a signal of
an increased risk of recurrent clinical cerebrovas-
cular events after the post-treatment magnetic
resonance imaging scan among patients treated with
open-cell stents compared with patients treated
with closed-cell stents; 15 patients in the former
group and 3 patients in the latter group experienced
a stroke or a transient ischemic attack up until the
end of available follow-up (hazard ratio: 3.09; 95%
conﬁdence interval: 0.89 to 10.7; p ¼ 0.075). This
observation supports the point made by Pacchioni
and colleagues that stent design may not only affect
the risk of periprocedural stroke, as has already
been shown in several studies (3,4), but also the risk
of delayed cerebrovascular events. Long-term data
from randomized controlled trials comparing stent-
ing versus endarterectomy for symptomatic carotid
stenosis have recently been pooled by the Carotid
Stenosis Trialists’ Collaboration and will provide
the basis for a more thorough examination of the
relationship between stent design and the occur-
rence of peri-procedural and delayed cerebrovas-
cular events (5).Henrik Gensicke, MD
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376:1062–73.Don’t Throw the Baby
Out With the Bath WaterWe read with interest the article by Uretsky et al. (1)
and would like to provide a few comments. The in-
vestigators did not describe if they included patients
with atrial ﬁbrillation and the number of cardiac cy-
cles used to assess mitral regurgitation (MR) by both
echocardiography and magnetic resonance imaging
(MRI) in such patients. In the presence of atrial
ﬁbrillation, variable RR intervals might affect both
echocardiography and MR calculations. With respect
to loading conditions, the overall group’s mean
values for blood pressure (BP) and heart rate (HR)
were comparable; however, the SD suggests that, for
an individual patient, BP and HR at the time of
echocardiography and MRI were likely not compara-
ble. It is also possible that MRI underestimated MR
volume in patients with mild aortic regurgitation
(AR), especially if AR was more than mild and
underestimated (we were not informed on how the
severity of AR was quantiﬁed). Table 4 shows that
patients with a progressive increase in MR severity as
seen by MRI had a progressive increase in left ven-
tricular (LV) end-diastolic diameter. LVEDD was
5.09  0.60 cm, 5.23  0.66 cm, and 6.11  0.59 cm,
respectively, and LV end-systolic diameter was
3.41  0.50 cm, 3.47  0.73 cm, and 4.07  0.53 cm,
respectively, in mild, moderate, and severe MR by
MRI. Because MR severity was calculated using LV
end-diastolic volume (EDV), the higher the LVEDV,
the more severe the MR according to MRI. Therefore,
in the presence of normal LV size (and EDV), MRI is
likely to underestimate MR severity. In addition, pa-
tients with higher LVEDVs are expected to have a
greater reduction in LVEDV post-MR surgery than
those with a normal LVEDV. Thus, instead of
concluding that MRI is a better method to assess MR
